Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROBIN: Zuranolone in Severe Postpartum Depression
NCT02978326Phase 3Completed
- Sponsor
- Biogen
- Start
- Jan 2017
- Primary completion
- Nov 2018
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zuranolone in postpartum depression (PPD) (3 arms), sponsored by Biogen. Primary endpoint: Change From Baseline in the 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15. Started Jan 2017; status: completed.
02
Drugs
zuranolone
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on NCT02978326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978326.